The Application of Ferroptosis in Diseases

Yangmin Qiu; Yue Cao; Wangjia Cao; Yifei Jia; Na Lu

doi:10.1016/j.phrs.2020.104919

The Application of Ferroptosis in Diseases

Pharmacol Res. 2020 Sep:159:104919. doi: 10.1016/j.phrs.2020.104919. Epub 2020 May 25.

Authors

Yangmin Qiu¹, Yue Cao¹, Wangjia Cao¹, Yifei Jia², Na Lu³

Affiliations

¹ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, People's Republic of China.
² State Key Laboratory of Quality Research in Chinses Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa university boulevard, Macau, People's Republic of China.
³ State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing, 210009, People's Republic of China. Electronic address: nalu@cpu.edu.cn.

PMID: 32464324
DOI: 10.1016/j.phrs.2020.104919

Abstract

Ferroptosis is a new kind of regulated cell death that is characterized by highly iron-dependent lipid peroxidation. Ferroptosis involves various biology processes, such as iron metabolism, lipid metabolism, oxidative stress and biosynthesis of nicotinamide adenine dinucleotide phosphate (NADPH), glutathione (GSH) and coenzyme Q10 (CoQ10). A growing body of evidence suggests that ferroptosis is associated with cancer and neurodegenerative diseases (Alzheimer's disease, Parkinson's disease and Huntington's disease). This finding has helped develop a novel cytoprotective strategy to protect cells in neurodegenerative, blood and heart diseases by inhibiting ferroptosis. Meanwhile, the selective induction of ferroptosis has been adopted as a potential treatment strategy in some kinds of cancer. This review aims to summarize the mechanism of ferroptosis regulation and relevance to pathological physiology.

Keywords: Deferasirox (PubChem CID: 214348); Deferoxamine (PubChem CID: 2973); Erastin (PubChem CID: 11214940); Ferrostatin-1 (PubChem CID: 4068248); Lapatinib (PubChem CID: 208908); RAS-selective lethal 3 (PubChem CID: 1750826); Sorafenib (PubChem CID: 216239); cancer; cell death; ferroptosis; iron metabolism; lipid peroxidation; reactive oxygen species.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use
Ferroptosis* / drug effects
Humans
Iron / metabolism*
Lipid Peroxidation* / drug effects
Neoplasms / drug therapy
Neoplasms / metabolism
Neoplasms / pathology*
Neurodegenerative Diseases / drug therapy
Neurodegenerative Diseases / metabolism
Neurodegenerative Diseases / pathology*
Neuroprotective Agents / therapeutic use
Reactive Oxygen Species / metabolism

Substances

Antineoplastic Agents
Neuroprotective Agents
Reactive Oxygen Species
Iron